Biogen grows in Q2, but Spinraza performance a concern

The performance was thanks largely to its under-pressure multiple sclerosis (MS) franchise, where combined sales of Tecfidera, Avonex, Plegridy and Tysabri totalled $2.2bn. ... palsy. One big binary decision awaiting the firm is a challenge

Biogen trumpets safety data for Tecfidera follow-up

to hear the outcome of a patent challenge on Tecfidera (dimethyl fumarate) in the US from Mylan. ... Whether that is enough to encourage payers to cover diroximel fumarate once cheaper generic Tecfidera products are available remains to be seen.

FDA starts review of Biogen’s Tecfidera follow-up for MS

The new drug is designed to improve on the safety profile of Biogen’s established MS blockbuster Tecfidera (dimethyl fumarate), particularly with regard to its gastrointestinal tolerability. ... of Tecfidera patients at one clinic stopped using the

Biogen files Tecfidera follow-up in the US

Biogen is also enrolling patients a head-to-head tolerability study versus Tecfidera with data due in mid-2019. ... Just when Tecfidera might become vulnerable to generic competition isn’t yet clear.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]